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ABSTRACT
Prostate cancer is the most common male cancer and androgen receptor (AR) 
is the major driver of the disease. Here we show that Enoyl-CoA delta isomerase 2 
(ECI2) is a novel AR-target that promotes prostate cancer cell survival. Increased 
ECI2 expression predicts mortality in prostate cancer patients (p = 0.0086). ECI2 
encodes for an enzyme involved in lipid metabolism, and we use multiple metabolite 
profiling platforms and RNA-seq to show that inhibition of ECI2 expression leads 
to decreased glucose utilization, accumulation of fatty acids and down-regulation 
of cell cycle related genes. In normal cells, decrease in fatty acid degradation is 
compensated by increased consumption of glucose, and here we demonstrate that 
prostate cancer cells are not able to respond to decreased fatty acid degradation. 
Instead, prostate cancer cells activate incomplete autophagy, which is followed 
by activation of the cell death response. Finally, we identified a clinically approved 
compound, perhexiline, which inhibits fatty acid degradation, and replicates the 
major findings for ECI2 knockdown. This work shows that prostate cancer cells 
require lipid degradation for survival and identifies a small molecule inhibitor with 
therapeutic potential.
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INTRODUCTION
Prostate cancer is the most common cancer in men 
and targeting androgen receptor (AR) is an effective 
treatment. In the clinical setting, inhibition of AR activity 
frequently leads to the development of castration-resistant 
prostate cancer, a condition with no curative treatment 
options [1, 2]. AR signaling remains active in castration-
resistant disease, and a recent study used chromatin 
immunoprecipitation (ChIP) coupled to sequencing (seq), 
to identify a gene signature of putative AR-target genes in 
this lethal form of cancer [3]. Among this signature was a 
poorly characterized enzyme, Enoyl-CoA delta isomerase 
2 (ECI2). ECI2 has been purified, and using enzymatic 
assays, was shown to catalyze isomerization of lipids [4]. 
Lipid metabolism is of high interest in prostate cancer, 
since it offers a route to intra-tumoral steroid-hormone 
synthesis after or during androgen deprivation therapy [5]. 
The importance of steroidogenesis is further underlined 
by the anti-androgen abiraterone, which targets steroid 
metabolism and offers clinical benefit for castration-
resistant prostate cancer patients [6].
The metabolic status of the normal prostate is 
different from the rest of the body due to the incomplete 
TCA cycle and secretion of citrate, a TCA metabolite, 
important for the viability of sperm [7]. In the early 
stages of prostate cancer, citrate secretion decreases, 
accompanied by a decrease in aerobic glycolysis, 
which ‘masks’ tumors from the conventional tracers 
of proliferating cells, such as glucose-PET [8, 9]. Lipid 
metabolizing enzymes are up-regulated in the early phase 
of prostate cancer and remain elevated throughout the 
disease progression, which suggests an active role in the 
disease [9]. In agreement with this, statin intake to lower 
blood cholesterol levels is associated with prostate cancer 
prevention [10]. The importance of lipid metabolism is 
exemplified further by the lipid producing enzyme, fatty 
acid synthase, which is over-expressed during prostate 
cancer progression and can be targeted with Orlistat, a 
drug approved for the treatment of obesity [11, 12].
Since AR activity and lipid metabolism appear 
important in prostate cancer, here we investigate ECI2, 
an AR-target gene. We show that ECI2 is over-expressed 
in prostate cancer patient samples in mRNA and protein 
levels, and that increased expression predicts poor 
outcome. Knockdown of ECI2 had minimal effect on 
gene expression in a cell line representing normal prostate 
epithelium but resulted in down-regulation of cell cycle-
associated genes in prostate cancer cells. The difference in 
gene expression translated to growth inhibition of prostate 
cancer cells, but had only modest effect on a cell line 
representing normal prostate epithelium. Integration of 
the RNA-seq data with metabolomics data revealed that 
inhibition of ECI2 expression led to acute metabolic stress 
in prostate cancer cells.
RESULTS
ECI2 is over-expressed in clinical prostate cancer
ECI2 was identified as a putative AR target gene in 
castration-resistant prostate cancer tissue samples using ChIP-seq 
technology [3]. As the first step, we evaluated ECI2 expression 
in matched benign and prostate cancer patient tissue samples, 
and observed a 2-fold increased expression of ECI2 mRNA 
(p =  0.024, Figure 1A). Encouraged by this result, we evaluated 
ECI2 protein level expression using immunohistochemistry, 
and found out that elevated ECI2 protein predicted mortality 
(p = 0.0086, Figure 1B, see also Supplementary Figure 1).
Since ECI2 was over-expressed in prostate cancer 
patient samples, we moved on to assess AR-dependent 
regulation of this gene. We re-analyzed AR ChIP-seq data 
from human tissue samples [3], and putative AR-binding 
site in castration-resistant prostate cancer patient samples 
was found inside the ECI2 gene body (chromosome 
coordinates in Human Genome 18: chr6:4,075,826-
4,076,114). In order to confirm these data, we designed 
primers against this site, and assessed potential AR binding 
using ChIP-qPCR. Androgen-stimulation resulted in 
6-fold increased AR binding to this site, once compared 
to vehicle and an IgG antibody control (Figure 2A). We 
next confirmed that androgen stimulation increases ECI2 
expression at the mRNA and protein levels in LNCaP and 
VCaP cells (Figure 2B and 2C). Information on the primers 
and probes used in this study for ChIP-qPCR and RT-PCR 
are to be found in Supplementary Table 3 and more detailed 
methodology is provided in supplementary information.
Since ECI2 was over-expressed in prostate cancer 
patient samples, we tested whether the enzyme is important 
for prostate cancer cell growth by following cell proliferation 
using life-cell imaging. ECI2 knockdown strongly inhibited 
proliferation of LNCaP prostate cancer cell line but had only 
modest effects on RWPE-1, a cell line derived from normal 
prostate epithelium (Figure 2D). In addition, knockdown of 
ECI2 activated cell death response in LNCaP cells (Figure 2E).
These data suggest that ECI2 has a role in promoting 
the proliferation of prostate cancer cells.
Metabolomic profiling after ECI2 knockdown 
revealed profound changes in lipid composition 
ECI2 has been reported to function in lipid processing and 
the enzyme has been shown to isomerize 3-cis-octenoyl-CoA 
to 2-trans-octenoyl-CoA [4] (Figure 3A). This isomerization 
reaction is important for the subsequent degradation of 
unsaturated lipids [4]. Degradation maintains correct lipid 
homeostasis, supports citric acid cycle by production of acetyl-
CoA and replenishes NADH and FADH pools.
ECI2 knockdown decreased glucose consumption 
and lactate production, as measured from cell culture 
media (Figure 3B). In order to get a clearer picture of the 
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prostate cancer cell metabolome after ECI2 knockdown, 
we used mass spectrometry-based untargeted metabolite 
profiling of intra-cellular metabolites. This approach 
revealed decrease in TCA cycle metabolites fumarate and 
malate, while serine accumulated (Figure 3C).
These changes suggest that ECI2 knockdown 
imposes an acute metabolic stress on cells. Therefore we 
would expect stress-resistance promoting pathways, such 
as autophagy, to be up-regulated [13]. ECI2 knockdown 
induced prominent accumulation of the canonical 
autophagy marker LC3 [14], in two prostate cancer cell 
lines, LNCaP and VCaP (Figure 3D). However, p62, an 
adaptor protein for autophagy [14], was not degraded, 
which suggests  incomplete autophagy and sustained stress. 
Indeed, prostate cancer cells were unable to respond to 
ECI2 knockdown induced metabolic stress, which resulted 
in cell death activation (PARP cleavage, Figure 3D).
The major task for ECI2 enzyme is believed 
to be lipid processing [4], and we observed choline 
accumulation in culture media after ECI2 knockdown 
(Figure 3B). Based on these facts, we performed 
targeted phospholipidomic profiling of LNCaP prostate 
cancer cells after ECI2 knockdown, which revealed 
accumulation of all major classes of phospholipids, 
phosphatidylserine (PS), phosphatidylcholine (PC), 
phosphatidylethanolamine (PE) and phosphatidylinositol 
(PI) (Figure 3E and Supplementary Figure 2). ECI2 
knockdown had prominent effect on the saturated lipids of 
PS and PI (Figure 3F). However, this lipid pool represents 
a minor fraction of total cellular lipids, and in this context 
it is important to point out that the most abundant lipids 
in scrambled condition were profoundly increased upon 
ECI2 knockdown (Supplementary Figure 2). For example 
lipids with single double-bond, especially 36:1, were 
prominently increased in all four lipid classes.
We next used Oil Red O staining to confirm a 
statistically significant increase of lipids (Supplementary 
Figure 3A). Based on Oil Red O staining, we noted possible 
accumulation of lipid droplets, and this was confirmed with 
AdipoRed stain (Supplementary Figure 3B).
We have so far shown that ECI2 knockdown 
inhibits cancer cell proliferation, which is associated with 
decreased glucose consumption and lipid accumulation. 
This caused acute stress and cell death activation, but 
exact mechanism(s) remain unclear.
ECI2 knockdown represses cell cycle associated 
genes
In order to better understand metabolomics data, we 
performed RNA-sequencing after ECI2 knockdown in the 
LNCaP prostate cancer cell line and RWPE-1 cell line, 
which represents normal prostate epithelial cells. In order to 
set stringent criteria to establish ECI2-dependent transcripts, 
we performed RNA-seq on two biological replicates and 
selected only the transcripts that were affected by both 
of the two siRNAs targeting ECI2. A summary of the 
differentially expressed genes in each cell-line and in each 
biological replicate is provided in supplementary Table 
6. Based on this approach, the expression of 4 genes was 
Figure 1: Enoyl-CoA delta isomerase 2 (ECI2) is over-expressed in prostate cancer. (A) ECI2 expression was evaluated in 
prostate cancer tissue samples. The data shown represents matched normal epithelium and adenocarcinoma from 20 radical prostatectomy 
specimens. Relative expression of the different transcripts were calculated using the comparative CT method, where the matched benign 
tissue of the same patient were set to 1 and normalized to the geometric mean CT value of GAPDH, TBP and 18s. Wilcoxon matched-pairs 
signed rank test was used to test for significance in the differential expression of ECI2 between the matched benign and cancer tissue. 
(B) Kaplan Meier curves for the low/medium group versus the high ECI2 expressing group. We evaluated whether ECI2 expression levels 
are associated with survival in prostate cancer patients. The difference in overall survival between the low / medium expressing group and 
high expressing group was 77 months vs 115 months, p = 0.0086. Here stating that an overview of the clinical cohorts use in Figures 1A 
and 1B and the statistical analysis are to be found in Supplementary Tables 2, 4 and 5.
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Figure 2: Androgen receptor (AR) regulates Enoyl-CoA delta isomerase 2 (ECI2) expression. (A) Chromatin 
immunoprecipitation (ChIP) of androgen receptor (AR) in VCaP cells. Cells were deprived of androgens for 3 days and treated either with 
1nM R1881 or vehicle, as indicated. The putative AR binding site for ECI2 was identified from a published AR ChIP-seq data set [3]. The 
data shown is representative of two biological replicates. (B) LNCaP and VCaP cells were treated as in A. Total mRNA was isolated at 
12 hours and the expression of ECI2 and actin was evaluated using RT-qPCR. The data shown are an average of three independent 
experiments with SEM, and significance was evaluated using paired samples Student’s t-test, *< 0.05. (C) LNCaP and VCaP cells were 
deprived of androgens for 3 days, treated either with 1nM R1881 or vehicle (-) and protein lysates were collected. Densitometry was used 
to evaluate ECI2 levels. (D) Western blot was used to confirm ECI2 knockdown in LNCaP and RWPE-1 cells after 96 hours. Densitometry 
was used to evaluate ECI2 levels. The growth rate of cells was evaluated with life-cell imaging. The data shown are an average of three 
independent biological replicates with SEM. The significance was evaluated using paired samples Student’s t-test, **< 0.01, ***< 0.001. 
(E) Cell death activation after ECI2 knockdown. LNCaP cells were reverse-transfected and allowed to attach for 24 hours. At this point, a 
dye detecting caspase 3/7 activation was added and cumulative activation of caspase 3/7 was followed in real-time using life-cell imaging. 
Data shown is an average of three biological replicates with SEM.
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Figure 3: Metabolomic profiling after ECI2 knockdown in LNCaP cells. (A) Reaction catalyzed by Enoyl-CoA Delta Isomerase 
2 (ECI2). (B) The level of extra-cellular lactate, glucose and choline were determined using nuclear magnetic resonance after 72 hours of 
ECI2 knockdown. The data are presented as % of complete media without cells and are an average (with SEM) of five biological replicates. 
The significance was evaluated using paired samples Student’s t-test, *< 0.05, ***< 0.001. (C) The levels of water-soluble intra-cellular 
metabolites were determined using mass-spectrometry after 72 hours of ECI2 knockdown. Only metabolites that were affected significantly 
by at least one siRNA are shown. Data shown are an average (with SEM) of five biological replicates. The significance was evaluated using 
paired samples Student’s t-test, *< 0.05, **< 0.01. (D) ECI2 knockdown in LNCaP (for 72 hours) and VCaP cells (for 96 hours). The data 
shown are representative of at least three biological replicates for LNCaP cells and two replicates for VCaP cells. Densitometry was used 
to evaluate signal intensity. (E) The levels of intra-cellular phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylethanolamine 
(PE) and phosphatidylinositol (PI)  were determined using mass-spectrometry after 72 hours of ECI2 knockdown. Identification of lipid 
composition is provided in Supplementary Figure 2. Data shown are an average (with SEM) of three biological replicates. The significance 
was evaluated using paired samples Student’s t-test, *< 0.05, **< 0.01. (F) The levels of saturated and un-saturated lipids were determined 
using mass-spectrometry after 72 hours of ECI2 knockdown (same data-set as presented in Figure 3E). Scrambled samples were set to 1 
for all four lipid classes, and siECI2 samples were normalized to this. Data shown are an average (with SEM) of three biological replicates. 
The significance was evaluated using paired samples Student’s t-test, *< 0.05, **< 0.01.
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altered in RWPE-1 cells and the expression of 102 genes 
was altered in LNCaP cells after ECI2 knockdown at the 
selected 48 hour time point (Figure 4A). We first inspected 
the individual genes differently regulated in RWPE-1 
and LNCaP cells. Interestingly, RWPE-1 but not LNCaP 
cells, increased the expression of stress-resistance factor 
HSPB1 (heat shock protein family B (small) member 1) 
(Supplementary Table 1), which is known to protect cells 
from stress-induced apoptosis [15]. On the other hand, we 
found a number of genes known to be over-expressed in 
prostate cancer and promote prostate cancer cell survival, 
which were profoundly down-regulated only in LNCaP 
cells (Supplementary Table 1). Two examples are MELK 
(Maternal Embryonic Leucine Zipper Kinase) [16] and 
WASF3 (WAS Protein Family Member 3) [17, 18]. These 
data support the hypothesis that ECI2 has more important 
function(s) in prostate cancer cells.
In order to understand potential transcriptional 
programs of how prostate cancer cells respond to 
knockdown of ECI2, we next focused on the genes that were 
up-regulated after ECI2 knockdown only in LNCaP cells and 
performed pathway enrichment analysis using the Database 
for Annotation, Visualization and Integrated Discovery 
(DAVID) [19, 20]. This analysis highlighted two pathways, 
‘p53 signaling pathway’ and ‘Chronic myeloid leukemia’, 
with one common gene, CDKN1A (Supplementary Table 1). 
CDKN1A functions as a cyclin-dependent kinase inhibitor 
[21]. We next performed the pathway enrichment analysis 
with the genes that were down-regulated in LNCaP cells 
after ECI2 knockdown. Four pathways were highlighted, 
and the most significant one was ‘Cell cycle’, through 
decreased expression of CDK1, CDC6, MAD2L1, CCND3, 
CDKN2C, CDC25A, WEE1 and CDC25B (Supplementary 
Table 1). We used RT-qPCR to confirm the statistically 
significant differential expression of CDKN1A, CDK1, 
CDC6, CDC25A and AURKB in LNCaP and RWPE-1 cells 
after ECI2 knockdown (Figure 4B). ECI2 knockdown also 
statistically significantly decreased the expression of CDC6 
in VCaP cells (Supplementary Figure 4).
RNA-seq and subsequent validation revealed that 
CDC6 is one of the most prominently down-regulated 
genes in both prostate cancer cell lines. Potential 
Figure 4: RNA-seq after ECI2 knockdown in LNCaP and RWPE-1 cells. The expression of ECI2 was reduced by treating 
LNCaP and RWPE-1 cells for 48 hours with siRNA and RNA was collected and used for RNA-seq. (A) Venn diagram shows the number 
of genes that were differentially regulated by both siRNAs in either LNCaP or RWPE-1 cells, and regulated differentially between the two 
cell lines. (B) Validation of the RNA-seq data using RT-qPCR. The data shown are an average of at least two biological replicates for both 
RNA-seq and validation, and the significance was evaluated using paired samples Student’s t-test, *< 0.05, **< 0.01, ***< 0.001.
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correlation between CDC6 expression and prostate cancer 
aggressiveness has not been previously evaluated, but 
this protein is normally found in proliferating cells [22]. 
We therefore evaluated the correlation between elevated 
CDC6 expression and metastasis in a cohort of high-risk 
prostate cancer patients [23]. In this cohort, increased 
CDC6 expression predicted metastasis (p = 7.41e-04), 
and was also prominently associated with prostate cancer-
specific mortality (p = 1.09e-02, Supplementary Figure 5).
So far, we have identified a gene, ECI2, for which 
knockdown inhibited prostate cancer cell proliferation 
and in addition suppressed expression of CDC6. Elevated 
expression of CDC6 is associated with poor patient 
outcome. Based on these data, ECI2, or more generally, 
lipid degradation, might represent a novel drug target to 
limit prostate cancer cell proliferation.
Targeting lipid degradation inhibits prostate 
cancer cell proliferation 
There are no drugs directly inhibiting ECI2 activity 
but small molecule inhibitors targeting lipid degradation 
are available. Some of these compounds, including 
perhexiline, are available clinically [24]. Perhexiline is 
used to inhibit degradation of lipids for energy production, 
and thereby to promote more oxygen-efficient utilization 
of glucose as an energy source in chronic ischemic 
cardiomyopathy [25]. Based on our metabolomics and 
RNA-seq data, prostate cancer cells are unable to increase 
glucose utilization once lipid degradation is inhibited. 
Instead, an acute metabolic stress is induced, which 
culminates in cell death response activation (Figure 3D). 
We hypothesized that perhexiline might be able to cause 
similar response in prostate cancer cells.
We first confirmed that perhexiline treatment leads 
to dose-dependent lipid accumulation, similar to that 
observed upon ECI2 knockdown (Figure 5A). This lipid 
accumulation was mirrored by concomitant decrease in 
prostate cancer cell proliferation (Figure 5B). Similar 
to ECI2 knockdown, prostate cancer cells responded 
by activation of incomplete autophagy, as measured by 
prominent accumulation of autophagy markers LC3 and 
adaptor protein p62 [14] (Figure 5C). Prostate cancer cells 
were unable to respond to perhexiline-induced metabolic 
stress, and higher doses induced cell-death, as measured by 
PARP cleavage and activation of caspases 3/7 (Figure 5C 
and 5D). In addition, this compound let to prominent down-
regulation of CDC6 (Supplementary Figure 6).
These data suggest that perhexiline could have 
potential in limiting the proliferation of prostate cancer cells, 
but one of the challenges in utilizing perhexiline in clinical 
setting are ‘poor-metabolizers’, patients who have altered 
activity of CYP2D6 (cytochrome P450 family 2 subfamily 
D member 6) [26]. This problem can be overcome by dose-
reduction and/or genetic testing [27]. The dose-limitation 
challenge motivated us to evaluate whether combinatorial 
treatment with perhexiline and anti-androgens would 
allow dose reduction. For these experiments, we selected 
a low dose of perhexiline (5 µM), which on its own led 
to prominent increase in intracellular lipid content but 
only modestly inhibited proliferation (Figure 5A and 5B). 
Interestingly, combinatorial treatment of LNCaP cells with 
perhexiline and either Abiraterone or Enzalutamide (MDV-
3100) almost completely blocked proliferation (Figure 5E).
Taken together, these data suggest that a novel 
AR target gene, ECI2, supports aberrant metabolic 
homeostasis of prostate cancer cells. Inhibition of lipid 
degradation either by knocking down this enzyme or by 
a small molecule inhibitor leads to metabolic stress and 
activation of the cell death response.
DISCUSSION
Prostate cancer is the most common cancer in men, 
and increased AR activity is associated with prostate 
cancer development and progression. AR-driven complex 
transcriptional programs have previously been used as a 
starting point to identify prostate cancer-specific metabolic 
vulnerabilities [28, 29]. In this study, we showed that 
ECI2, an enzyme involved in degradation of unsaturated 
lipids, is a direct AR-target and over-expressed in clinical 
prostate cancer (Figures 1 and 2). Both ECI2 and CDC6 
can be induced by AR (this paper and Mallik & al. 
2008 [30], respectively). Inhibition of ECI2 expression 
decreased the growth rate and activated cell death response 
in prostate cancer cells (Figures 2D and 3D).
Proliferating cancer cells have increased need for 
lipids [31]. Interestingly, here we observed that inhibition 
of ECI2 expression and perhexiline treatment led to 
prominent accumulation of lipids into cells, which did 
not promote cancer cell proliferation. Normal prostate 
cells have an incomplete TCA cycle and therefore cannot 
rely on typical energy producing pathways [9, 11]. This 
metabolic adaptation has been shown to sensitize prostate 
cancer cells to compounds inhibiting mitochondrial 
activity, and specifically sensitize the cancer cells to other 
treatments [32]. Here we propose that this metabolic 
adaptation forces prostate cancer cells to derive a 
significant fraction of their energy through alternative 
pathways, such as lipid degradation. In agreement with 
this model, inhibition of lipid degradation decreased 
glucose utilization and led to accumulation of  starvation 
/autophagy markers (Figure 3D and Figure 5C) [14]. 
Instead of successful, cell-survival promoting autophagy, 
inhibition of lipid degradation led to the activation of 
the cell death response in prostate cancer cells. Similar 
dependency on fatty acid oxidation was recently reported 
in MYC-overexpressing triple-negative breast cancer cells 
[33]. In breast cancer cells, perhexiline has been shown 
to inhibit HER3-signaling [34] and induce autophagy 
[35]. It is not known whether these effects are caused 
directly by the compound or are down-stream effects from 
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inhibition of lipid metabolism, as it is well established 
that perhexiline affects lipid metabolism of cancer cells 
[36, 37]. Interestingly, a number of studies have reported 
that perhexiline is able to sensitize, and in some cases, 
reverse resistance, to clinically relevant drugs, including 
doxorubicin in breast cancer cells [38] and murine 
leukemia cell line [39] and cisplatin in neuroblastoma 
cells [40]. We are the first to show that perhexiline has 
prominent anti-tumor activity once combined with second-
generation anti-androgens, Abiraterone and Enzalutamide 
(Figure 5E). However, because cancer metabolism is 
influenced by the tumour microenvironment and can be 
Figure 5: Lipid degradation inhibitor perhexiline activates cell death in prostate cancer cells. (A) Oil red O staining of 
LNCaP cells after 24 hours of perhexiline treatment. Data shown are an average (with SEM) of five biological replicates. The significance 
was evaluated using paired samples Student’s t-test, *< 0.05. (B) LNCaP cells were treated with increasing doses of perhexiline and growth 
rate was followed using life-cell imaging. Data shown is an average of four biological replicates with SEM. Significance was evaluated 
using paired samples Student’s t-test, *< 0.05, **< 0.01, ***< 0.001. (C) LNCaP cells were treated with perhexiline for 4 hours or 24 hours, 
and protein lysates were collected for western blotting. The data shown are representative of three biological replicates. Densitometry was 
used to evaluate signal intensity. (D) LNCaP cells were treated with perhexiline as indicated and cell death activation was evaluated using 
life-cell imaging detecting activation of caspases 3 and 7.  Data shown is an average of four biological replicates with SEM. Significance was 
evaluated with paired samples Student’s t-test, *< 0.05, **< 0.01. (E) LNCaP cells were treated with perhexiline alone or in combination 
with androgen deprivation therapy (either Abiraterone or MDV-3100) and growth rate was followed using life-cell imaging. Data shown 
are an average of four biological replicates with SEM. Significance was evaluated using paired samples Student’s t-test, *< 0.05. Red stars 
indicate comparison between perhexiline and combinatorial treatment, while green stars indicate comparison between androgen deprivation 
and combinatorial treatment.
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compartmentalized between different cell populations 
[41–43], it will be important in the future to extend studies 
of ECI2 function and perhexiline response to more patient-
derived pre-clinical models (eg. Explants or PDX) as a 
stepping stone to clinical trials.
Perhexiline can cause severe toxic side-effects, 
including neuro- and hepatotoxicity, in a sub-set of patients 
[27]. The majority of the side-effects are caused by the 
complex pharmacokinetic profile of this compound, which 
results in bio-accumulation in small number of patients 
and sub-sequent toxicicity [26, 27]. This toxicity can be 
minimized by sustained monitoring of perhexiline plasma 
levels and adjusting the drug-dosing to result in blood 
levels below 600 ng/ml [44–46]. It is noteworthy that the 
anti-tumor activity of perhexiline has been demonstrated 
in mouse models of several cancers, including breast 
cancer [34], neuroblastoma [40] and chronic lymphocytic 
leukemia [36] with no obvious toxicity. 
Normal cells are able to compensate for decreased 
lipid degradation through increased glucose consumption, 
and therefore inhibition of lipid utilization is not toxic 
[47]. In fact, certain tissues essentially require glucose 
as an energy source, and in certain instances inhibition of 
lipid oxidation is beneficial. This is the case in chronic 
ischemic cardiomyopathy, a condition with limited oxygen 
supply to heart tissue [25].
In summary, we propose that prostate cancer cells 
essentially require lipid degradation for energy production 
and to sustain proliferation. Failure to adapt to inhibition 
of lipid degradation leads to profound changes in total 
metabolome and eventually activation of the cell death 
response in prostate cancer cells. 
Targeting cancer-cell specific metabolic 
vulnerabilities with approved compounds is an exciting 
approach, and should speed the development of new 
combinatorial therapies. Clinical trials using metabolic 
inhibitors in combination with established cancer-
specific drugs are on-going, including compounds such 
as metformin (for details see: https://clinicaltrials.gov/), 
and scientific community will likely see more of those 
in the future. Our data provide evidence to combine anti-
androgens with compounds targeting lipid metabolism.
MATERIALS AND METHODS
Evaluation of ECI2 expression in patient samples
RNA extracted from surgical specimens was 
obtained from Roswell Park Cancer Institute. These 
samples are covered by an approval (BDR 034313) from 
the Office of Research Subject Protection. The Salford 
prostate TMA consisting of diagnostic needle core biopsies 
from 144 patients attending the Urology clinic of Salford 
Royal NHS Foundation Trust was covered by MCRC 
Biobank Ethics 10_NOCL_02, Manchester, UK. Detailed 
protocols are provided in supplementary materials.
Cell lines, maintenance and treatments
Cells were obtained from ATCC and maintained 
according to ATCC guidelines. To simulate androgen 
deprivation, cells were kept in phenol-red free media 
supplemented with charcoal-stripped serum. Knockdown 
of ECI2 was performed with RNAiMAX reagent (Thermo 
Fisher Scientific) according to manufacturer’s instructions. 
ECI2 targeting siRNAs were obtained from Qiagen 
(SI04202282 and SI04201848). Perhexiline was purchased 
from Sigma (catalogue number: SML0120-10MG). More 
detailed protocols for cell lysate preparation, Oil Red O 
staining (obtained from Sigma, catalogue number: O1391-
250ML) and Lipid Tox staining (obtained from Life 
Technologies, catalogue number: H34475) are available 
in supplementary materials.
Analysis of viability, growth rate and caspase 
activity
Cells were plated on 384-well plates one day 
before treatment. Caspase 3/7 activation was detected 
using IncuCyte® Caspase-3/7 Apoptosis Assay Reagent 
(EssenBiosciences, catalogue number 4440) and using 
the IncuCyte instrument (EssenBiosciences) according to 
manufacturer’s instructions. Growth rates were determined 
using the IncuCyte instrument according to manufacturer’s 
instructions. In brief: in order to determine growth rate of 
cells, cells were reverse-transfected into 384-well plate, 
and the plate was placed into IncuCyte instrument. Using 
this instrument, cells were imaged as indicated in the 
figures and confluency was determined using the built-in 
software that comes along with the instrument. In order to 
determine growth rate of cells after compound treatment, 
cells were plated one day before the treatments, and on the 
next day, cells were treated as indicated in the figure and 
growth rate was followed by life-cell imaging.
Metabolomics, RNA-seq and mayo cohort 
analysis
Detailed protocols and analysis of Gas-
chromatography mass spectrometry, 1H NMR 
spectroscopy of cell culture media, lipidomics and RNA-
seq, ChIP-seq and analysis of Mayo cohort samples for 
met- and prostate cancer specific mortality-free survival 
are provided in supplementary materials. RNA-seq data 
has been made available: http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?token=wxydygwubzcxxax&acc=G
SE75035 for editor / reviewers, and will be made publicly 
available once the manuscript has been accepted. The 
processed files are compressed folders containing multiple 
output files from CuffDiff runs estimating differentially 
expressed transcripts between the indicated ECI2 siRNA 
treated cells versus cells treated with Scrambled siRNAs 
(see Trapnell et al., 2012 for more info [48]).
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